In a young female patient who has experienced two seizures and has a normal brain CT scan, which antiepileptic drug should be initiated?

Start Lamotrigine or Levetiracetam as First-Line Treatment

For a young female patient with two unprovoked seizures and normal brain CT, initiate antiepileptic drug treatment with either lamotrigine or levetiracetam as first-line monotherapy. Given the patient's demographics (young female of childbearing potential), lamotrigine is the preferred choice due to its superior tolerability profile and lower teratogenic risk compared to other options 1.

Why Treatment Should Be Started Now

After two unprovoked seizures occurring within a reasonable timeframe (typically <6-12 months), consensus supports immediate treatment initiation 2. While treating after the first seizure reduces recurrence risk at one and five years, it doesn't improve long-term remission rates 3. However, with two seizures already documented, the recurrence risk is sufficiently high to warrant treatment, particularly if these seizures had significant symptomatology that would impact quality of life.

Seizure Type Determines Drug Selection

The normal CT suggests this is likely focal onset epilepsy (most common in young adults) rather than a structural lesion. If seizure semiology or EEG confirms focal seizures:

First-Line Options for Focal Seizures:

Lamotrigine shows the best overall profile:

• Lowest treatment failure rate for any reason compared to most other AEDs 1
• Superior to carbamazepine (the traditional first-line) with HR 1.26 (95% CI 1.10-1.44) for treatment failure 1
• Particularly appropriate for women of childbearing age due to lower teratogenic risk
• Better tolerated than older agents like carbamazepine, phenytoin, and valproate 1

Levetiracetam is equally acceptable:

• No significant difference from lamotrigine for treatment failure outcomes 1
• Faster titration possible (can reach therapeutic dose within days vs. weeks for lamotrigine)
• No drug interactions
• Consider if rapid seizure control is prioritized over the slower lamotrigine titration

If Generalized Tonic-Clonic Seizures (with or without other generalized seizure types):

Avoid sodium valproate in this young female patient despite it being first-line for generalized seizures, due to:

• Teratogenic effects (neural tube defects, developmental delays)
• Weight gain and PCOS risk
• Hair loss

Use lamotrigine or levetiracetam instead:

• Both show no significant difference from valproate for treatment failure in generalized epilepsy 1
• Lamotrigine: RR 1.06 (95% CI 0.81-1.37) vs. valproate 1
• Levetiracetam: RR 1.13 (95% CI 0.89-1.42) vs. valproate 1

Drugs to Avoid in This Patient

Carbamazepine - Despite being traditional first-line, it performs worse than lamotrigine for treatment failure and has more drug interactions 1

Phenytoin - Inferior efficacy (HR 1.44 vs. lamotrigine) and significant cosmetic side effects problematic for young women 1

Sodium valproate - Absolutely contraindicated in women of childbearing potential unless no alternatives exist and strict pregnancy prevention measures are in place

Topiramate - Higher treatment failure rate (HR 1.50 vs. lamotrigine) and cognitive side effects 1

Gabapentin - Poorest performance among newer AEDs (HR 1.53 vs. lamotrigine for treatment failure) 1

Critical Titration Considerations

Lamotrigine requires slow titration to prevent Stevens-Johnson syndrome:

• Start 25 mg daily for 2 weeks
• Increase to 50 mg daily for 2 weeks
• Then increase by 50 mg every 1-2 weeks to target dose (typically 200-400 mg/day in divided doses)
• Even slower if on valproate (which you should avoid anyway)

Levetiracetam allows rapid titration:

• Can start at 500 mg twice daily and increase to 1000 mg twice daily within one week if needed
• Maximum typically 3000 mg/day

Expected Outcomes

Treatment will reduce seizure recurrence risk but won't necessarily improve long-term remission rates 3. Approximately 60-70% of patients achieve long-term remission with first AED 4. Adverse events are more common with immediate treatment (RR 1.49) but must be balanced against seizure recurrence risk and quality of life impact 3.

Common Pitfalls to Avoid

• Don't use valproate in young women - This cannot be overstated given teratogenicity risks
• Don't rush lamotrigine titration - Rash risk increases significantly with rapid escalation
• Don't assume normal CT rules out epilepsy - Most epilepsy has no structural correlate on CT; MRI is more sensitive if imaging is needed
• Don't delay treatment waiting for EEG - If clinical diagnosis is clear with two unprovoked seizures, treatment can begin while awaiting EEG confirmation